September 9, 2020 Comments Off on Patent delisted for Boehringer Ingelheim drug GLYXAMBI Posted in: Uncategorized
Annual Drug Patent Expirations for GLYXAMBI Glyxambi is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from two suppliers. There are eleven patents…
The post Patent delisted for Boehringer Ingelheim drug GLYXAMBI ap…
September 9, 2020 Comments Off on Patent delisted for Boehringer Ingelheim drug OFEV Posted in: Uncategorized
Annual Drug Patent Expirations for OFEV Ofev is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are five patents…
The post Patent delisted for Boehringer Ingelheim drug OFEV appeared first on…